111 related articles for article (PubMed ID: 9580631)
1. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
2. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
3. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
Costa B; Giagnoni G; Colleoni M
Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
[TBL] [Abstract][Full Text] [Related]
4. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?
Caberlotto L; Rimondini R; Hansson A; Eriksson S; Heilig M
Neuropsychopharmacology; 2004 Jan; 29(1):15-22. PubMed ID: 12968131
[TBL] [Abstract][Full Text] [Related]
5. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
8. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
Tsou K; Patrick SL; Walker JM
Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
[TBL] [Abstract][Full Text] [Related]
9. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
10. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
11. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic system does not play a major role in the precipitated cannabinoid withdrawal syndrome.
Sañudo-Peña MC; Force M; Tsou K; McLemore G; Roberts L; Walker JM
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1121-4. PubMed ID: 11216447
[TBL] [Abstract][Full Text] [Related]
13. Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Navarro M; Carrera MR; Fratta W; Valverde O; Cossu G; Fattore L; Chowen JA; Gomez R; del Arco I; Villanua MA; Maldonado R; Koob GF; Rodriguez de Fonseca F
J Neurosci; 2001 Jul; 21(14):5344-50. PubMed ID: 11438610
[TBL] [Abstract][Full Text] [Related]
14. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.
Costa B; Colleoni M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1103-8. PubMed ID: 11189200
[TBL] [Abstract][Full Text] [Related]
15. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.
Mas-Nieto M; Pommier B; Tzavara ET; Caneparo A; Da Nascimento S; Le Fur G; Roques BP; Noble F
Br J Pharmacol; 2001 Apr; 132(8):1809-16. PubMed ID: 11309253
[TBL] [Abstract][Full Text] [Related]
16. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats.
Navarro M; Chowen J; Rocío A Carrera M; del Arco I; Villanúa MA; Martin Y; Roberts AJ; Koob GF; de Fonseca FR
Neuroreport; 1998 Oct; 9(15):3397-402. PubMed ID: 9855288
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.
Aceto MD; Scates SM; Martin BB
Eur J Pharmacol; 2001 Mar; 416(1-2):75-81. PubMed ID: 11282115
[TBL] [Abstract][Full Text] [Related]
18. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
Freedland CS; Whitlow CT; Smith HR; Porrino LJ
Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
[TBL] [Abstract][Full Text] [Related]
19. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals.
Lallemand F; Soubrié P; De Witte P
Alcohol Alcohol; 2004; 39(6):486-92. PubMed ID: 15466898
[TBL] [Abstract][Full Text] [Related]
20. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
Beardsley PM; Martin BR
Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]